• CiNii Researchナレッジグラフ検索機能（試行版）をCiNii Labsにて公開しました
  • 「研究データ」「根拠データ」の収録について
  • CiNii Books機能統合対応の追加実施をいたしました

    • ディビゲル<sup>®</sup> 1 mg使用中の患者の理解度と使用感調査

    DOI Web Site Web Site PubMed 参考文献4件 オープンアクセス

    書誌事項

    タイトル別名
    • The Investigation of Understanding and Comfort of Patients Taking Divigel<sup>®</sup> 1 mg
    • ディビゲル1mg使用中の患者の理解度と使用感調査
    • ディビゲル 1mg シヨウ チュウ ノ カンジャ ノ リカイド ト シヨウカン チョウサ
    公開日
    2014-04-01
    資源種別
    journal article
    DOI
    • 10.1248/yakushi.13-00246
    公開者
    公益社団法人 日本薬学会

    この論文をさがす

    説明

    Hormone replacement therapy (HRT) given by injection or administered orally or topically can improve the QOL of patients with menopausal symptoms. Because patient comfort is influenced largely by the dosage form, pharmacists should understand the properties of each dosage form and provide appropriate information to individual patients. In this study, we investigated the understanding of medicines and diseases of patients receiving HRT and discuss the approaches pharmacists can take to improve patients' adherence. Thirty-seven patients (mean age 51.7±3.6 years) taking estradiol gel (Divigel® 1 mg) completed a questionnaire asked by their pharmacist. Responses indicated 70% of patients failed to use the gel as prescribed, and they had poor knowledge of both the sites where the gel shouldn't be applied and appropriate measures to take if having forgotten to apply the gel (43% and 11% correct understanding, respectively). Since the duration of HRT treatment for menopausal symptom is 2-5 years, patients should be administered the minimum effective dose in the shortest amount of time. Hence it is important to maintain patients' adherence particularly in this limited administration period. HRT guidelines define HRT outcome as not only improvement of menopausal symptoms but also suppression of bone resorption, improvement of glucose and lipid metabolism, and reduced prevalence of Alzheimer's disease. Accordingly, pharmacists should facilitate proper adherence to HRT to improve and maintain women's QOL in the perimenopausal period, necessitating they actively provide pharmaceutical care such as preparing useful instructions patients can repeatedly use and periodically checking patients' understanding of their HRT medications.<br>

    収録刊行物

    • 薬学雑誌

      薬学雑誌 134 (4), 575-580, 2014-04-01

      公益社団法人 日本薬学会

    参考文献 (4)*注記

    もっと見る

    キーワード

    詳細情報 詳細情報について

    問題の指摘

    ページトップへ